Acetyl-L-carnitine (ALCAR)

What it is

The body makes carnitine itself, in the liver, kidneys and brain, from the amino acids lysine and methionine. About 95 percent of it is stored in heart and skeletal muscle. ALCAR is carnitine with an attached acetyl group. The brain, liver and kidneys produce it with an enzyme of their own.

The difference from ordinary L-carnitine is not just chemistry. After both oral and intravenous administration, the ALCAR concentration in the cerebrospinal fluid rises, so the substance crosses the blood-brain barrier. After a single dose of 500 milligrams, the blood level of healthy men reached its maximum after 3.1 hours, and the half-life was 4.2 hours.

How it is supposed to work

Three routes are discussed. First, energy metabolism: ALCAR helps move fatty acids from the cytoplasm into the mitochondria, where they are burned. Second, the acetyl group itself: it is needed for the formation of acetylcholine, a messenger for memory and attention. Third, effects on nerve cell membranes and the regeneration of peripheral nerves.

That ALCAR plays these roles in metabolism is biochemically well established. How strongly an additional intake changes them in humans, by contrast, has only been measured indirectly via clinical endpoints — not via the chain of action itself.

What ALCAR is actually used for

In Italy, ALCAR is a prescription medicine. The summary of product characteristics lists mechanical and inflammatory damage to peripheral nerves as the indication, with 0.5 to 1.5 grams per day, divided into 2 to 3 doses. In Germany it is sold as an ingredient in dietary supplements.

Research has concentrated mainly on four fields: depression, nerve pain in diabetes, memory disorders in old age and fatigue. In all four there are controlled studies in humans, and in all four there are positive signals. How robust they are differs considerably.

Energy in old age

ALCAR’s reputation for energy does have a basis, just not in young healthy people. Malaguarnera and colleagues gave ALCAR or placebo to 96 people between 71 and 88 years of age who suffered from persistent fatigue. At the end, the score on the Fatigue Severity Scale fell by 22.5 points in the ALCAR group and rose by 1.2 under placebo. The brief cognitive test MMSE improved by 3.4 versus 0.5 points. That is a clear result, but from a single research group and not yet independently repeated.

What the studies show

Meta-analysis on depressive symptoms

12 randomized studies, 11 of them with ALCAR as the sole treatment, 791 participants in total, 65 percent women. Against placebo or no treatment, the effect size was SMD -1.10, with a confidence interval of -1.65 to -0.56. Against antidepressants no difference was measurable, and side effects were less frequent under ALCAR. The authors themselves write that large studies must confirm or refute the findings, because the individual studies were small and very heterogeneous (I² 86 percent).

Cochrane review on diabetic nerve pain

4 studies with 907 participants, 3 of them placebo-controlled with 1,500, 2,000 or 3,000 milligrams per day over 6 to 12 months. Pooled, pain fell by 9.16 millimeters on the 0 to 100 scale. Up to 1,500 milligrams per day, no difference from placebo was discernible; above that it was 14.93 millimeters. The authors rate the certainty of this evidence as very low, and all four studies had a connection to the manufacturer.

SWOG S0715: the study with the reverse result

409 evaluable women with breast cancer received 3,000 milligrams of ALCAR per day or placebo for 24 weeks during taxane chemotherapy, in the hope of preventing nerve damage. After 12 weeks there was no difference. After 24 weeks, the ALCAR group had significantly more neuropathy (p = 0.01), and severe neurotoxicity occurred 8 times instead of once. In follow-up over 2 years, the disadvantage persisted.

Where the data stop

The biggest gap concerns exactly the group to which ALCAR is most often sold: healthy adults who want more energy and concentration. A Cochrane review found only 2 studies on this; essentially, what could be evaluated was a 3-day trial with ordinary L-carnitine in young adults. It showed no effect, but the authors stress that no conclusion can be drawn because of the thin and poorly reported data. That is not proof that ALCAR does not work in healthy people. It has simply not been studied. The positive fields also have limits. In depression, the studies were small and very heterogeneous. In nerve pain, the evidence is very uncertain and close to the manufacturer. In Alzheimer’s dementia, the Cochrane review found an advantage only for the clinical global impression after 12 and 24 weeks, not in memory tests or in daily life, and considers chance possible given so many comparisons. And for the often-cited TMAO signal there are data for L-carnitine; human data specifically on ALCAR could not be found.

Status, approval and legal

In Germany, ALCAR is on the market as an ingredient in dietary supplements; there is no statutory maximum amount. Authorized health claims do not exist: in 2018 EFSA saw no cause-and-effect relationship between L-carnitine and lipid metabolism, and according to the Verbraucherzentrale (German consumer advice centre), claims on energy and cognition were also rejected. In Italy, ALCAR is approved as a prescription medicine for damage to peripheral nerves. Carnitine is not on the WADA prohibited list for 2026; prohibited in general, however, are infusions or injections of more than 100 milliliters per 12 hours outside a hospital.

Safety

In the studies, ALCAR was mostly well tolerated. In the Cochrane review on nerve pain, 6 of 147 participants on a high dose dropped out because of side effects, versus 2 of 147 on placebo, mainly because of headache, abnormal sensations and gastrointestinal complaints. For carnitine in general, the NIH lists nausea, diarrhea, abdominal cramps and a fishy body odor from about 3 grams per day. There is no official upper limit. Three groups should talk to a doctor beforehand. Anyone receiving chemotherapy with taxanes, because of the results from SWOG S0715. Anyone taking thyroid hormones, because L-carnitine slows their action in the cells. Anyone taking coumarin-type anticoagulants, because case reports describe an enhanced effect. In seizure disorders, the NIH lists seizures as a possible consequence. There are no data on pregnancy and breastfeeding.

Sources

• Veronese et al., Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms, Psychosomatic Medicine 2018
• Kumar et al., Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders, Neuropsychiatric Disease and Treatment 2026
• Rolim et al., Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy, Cochrane Database of Systematic Reviews 2019
• Hershman et al., Randomized trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy, Journal of Clinical Oncology 2013
• Chen et al., L-carnitine for cognitive enhancement in people without cognitive impairment, Cochrane Database of Systematic Reviews 2017
• Hudson and Tabet, Acetyl-L-carnitine for dementia, Cochrane Database of Systematic Reviews 2003
• Montgomery et al., Meta-analysis of acetyl-L-carnitine in mild cognitive impairment and mild Alzheimer disease, International Clinical Psychopharmacology 2003
• Pennisi et al., Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders, Nutrients 2020
• NIH Office of Dietary Supplements, Carnitine – Fact Sheet for Health Professionals
• EFSA, L-carnitine and contribution to normal lipid metabolism, EFSA Journal 2018